DiaMedica Therapeutics (DMAC) Earnings Analysis
DiaMedica Therapeutics (DMAC) has no confirmed upcoming earnings date. Last quarter (2026-03-30) it beat with EPS -0.17 USD vs -0.17 USD est (0%). It has beaten estimates in 1/3 recent quarters (33%). Trailing P/E -9.77.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does DMAC next report earnings?
No confirmed upcoming earnings date is currently scheduled for DMAC. This page updates as the calendar is published.
DMAC earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-30 | -0.17 USD | -0.17 USD | 0% | Beat |
| 2025-11-12 | -0.17 USD | -0.15 USD | -13.3% | Miss |
| 2025-03-17 | -0.18 USD | -0.17 USD | -5.9% | Miss |
Beat rate: 1/3 (33%) over reported quarters with consensus data.
DMAC valuation and analyst view
| Trailing P/E | -9.77 |
|---|---|
| Trailing EPS | -0.65251 USD |
| Price / book | 7.90 |
| Dividend yield | 0.00% |
| Market cap | 0.38B |
| Analyst consensus | Buy (6 buy / 0 hold / 0 sell) |
Related research pages
Frequently asked questions
When is DiaMedica Therapeutics (DMAC)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for DMAC. This page updates as the calendar is published.
Did DMAC beat earnings last quarter?
In its 2026-03-30 report, DMAC posted EPS of -0.17 USD versus a -0.17 USD estimate — a beat of 0%.
What is DMAC's earnings track record?
Over the last 3 reported quarters with consensus data, DMAC beat estimates 1 times (33%).
What is DMAC's current P/E ratio and EPS?
DMAC trades at a trailing P/E of -9.77 on trailing EPS of -0.6525139008456228 USD.
What do analysts rate DMAC?
Analyst consensus is "Buy" across 6 ratings (0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell).